Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cellebrite DI (CLBT) Non-Current Deffered Revenue (2020 - 2025)

Cellebrite DI (CLBT) has 6 years of Non-Current Deffered Revenue data on record, last reported at $49.5 million in Q4 2025.

  • For Q4 2025, Non-Current Deffered Revenue rose 9.46% year-over-year to $49.5 million; the TTM value through Dec 2025 reached $49.5 million, up 9.46%, while the annual FY2025 figure was $49.5 million, 9.46% up from the prior year.
  • Non-Current Deffered Revenue reached $49.5 million in Q4 2025 per CLBT's latest filing, up from $45.2 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $49.5 million in Q4 2025 and bottomed at $36.4 million in Q4 2021.
  • Average Non-Current Deffered Revenue over 5 years is $44.1 million, with a median of $45.2 million recorded in 2024.
  • Peak YoY movement for Non-Current Deffered Revenue: rose 15.78% in 2022, then dropped 3.93% in 2024.
  • A 5-year view of Non-Current Deffered Revenue shows it stood at $36.4 million in 2021, then increased by 15.78% to $42.2 million in 2022, then rose by 11.68% to $47.1 million in 2023, then dropped by 3.93% to $45.2 million in 2024, then increased by 9.46% to $49.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non-Current Deffered Revenue were $49.5 million in Q4 2025, $45.2 million in Q4 2024, and $47.1 million in Q4 2023.